Skye Bioscience, Inc. - Common Stock (SKYE)

Which stocks have an unusual volume on Tuesday?

Curious about what's happening in today's session? Check out the latest stock movements and price changes.

Stay up-to-date with the latest market trends in the middle of the day on Monday. Explore the top gainers and losers during today's session in our detailed report.

Discover the top movers in Monday's pre-market session and stay informed about market dynamics.

Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes.

Skye shares surge after new data shows nimacimab reduces weight over 30% with tirzepatide, with stable potency and promising obesity treatment potential.

Curious about what's happening in today's session? Check out the latest stock movements and price changes.

There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Tuesday.

Looking for insights into the US markets one hour before the close of the markets on Tuesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.

Skye Bioscience is developing a peripheral restricted CB1 antibody to treat obesity by restoring leptin sensitivity and increasing fat metabolism, while avoiding the CB1-induced THC/neuro side effects. This has significant potential.

Novo Nordisk announced positive Phase 2a trial results for monlunabant, showing significant weight loss with a 10 mg dose. However, investors reacted to limited gains at higher doses. Corbus Pharmaceuticals and Skye Bioscience stocks dropped as all three companies explore CB1 inhibition in obesity treatment.

Although fraught with risk, these biotech exposures bring enormous upside potential.

The company is focusing on obesity treatment after its glaucoma drug failed.